AbCellera Biologics (ABCL) Short term Debt (2020 - 2025)
AbCellera Biologics' (ABCL) quarterly Short term Debt came in at $8.8 million in Q1 2025, down 82.95% YoY from $51.4 million in Q1 2024, and up 8.46% on a QoQ basis from $8.1 million in Q4 2024.
AbCellera Biologics (ABCL) Short term Debt (2020 - 2025) Analysis & Trends
AbCellera Biologics (ABCL) has 6 years of Short term Debt data on file, last reported at $8.8 million in Q1 2025.
- Quarterly Short term Debt fell 82.95% year-over-year to $8.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $8.8 million (down 82.95% YoY) and the FY2024 annual result came in at $8.1 million, down 83.98% from the prior year.
- Short term Debt climbed to $8.8 million in Q1 2025, from $8.1 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $54.9 million in Q2 2023 to a low of $8.1 million in Q4 2024.
- A 5-year average of $30.0 million and a median of $27.5 million in 2022 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2022 — Short term Debt soared 195.99% — and 2024, when it slumped 83.98%.
- Tracing ABCL's Short term Debt over 5 years: stood at $22.9 million in 2021, then jumped by 92.77% to $44.2 million in 2022, then advanced by 14.17% to $50.5 million in 2023, then tumbled by 83.98% to $8.1 million in 2024, then climbed by 8.46% to $8.8 million in 2025.
- The last three Short term Debt figures came in at $8.8 million (Q1 2025), $8.1 million (Q4 2024), and $20.2 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 8.77 Mn |
| Dec 31, 2024 | 8.09 Mn |
| Sep 30, 2024 | 20.22 Mn |
| Jun 30, 2024 | 20.03 Mn |
| Mar 31, 2024 | 51.43 Mn |
| Dec 31, 2023 | 50.48 Mn |
| Sep 30, 2023 | 53.93 Mn |
| Jun 30, 2023 | 54.87 Mn |
| Mar 31, 2023 | 42.88 Mn |
| Dec 31, 2022 | 44.21 Mn |
| Sep 30, 2022 | 32.53 Mn |
| Jun 30, 2022 | 34.25 Mn |
| Mar 31, 2022 | 27.50 Mn |
| Dec 31, 2021 | 22.93 Mn |
| Sep 30, 2021 | 12.12 Mn |
| Jun 30, 2021 | 11.57 Mn |
| Mar 31, 2021 | 13.76 Mn |
| Dec 31, 2020 | 13.41 Mn |